What to expectSo, what could we expect from the Shire deal, if it goes through, and other deals that may come thereafter. Perhaps this is a good comparison: Seattle Genetics, Inc. (NASDAQ:SGEN) entered into a collaboration agreement with Abbott (NYSE:ABT) under which Abbott will pay an upfront fee of 8 million for rights to utilize Seattle Genetics’ antibody-drug conjugate (ADC) technology with antibodies to a single oncology target....Even if BTI gets 5 mil up front, bearing in mind this would be just first of many to come deals, that would be a boon for the 23M market cap company.TB